NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
Clinical Trials
11 trialsNCT02351700 2021-10-21
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
St. Joseph's Hospital and Medical Center, Phoenix
Phase 4 Completed
NCT00939523 2020-01-22
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT02354508 2019-12-10
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis
Phase 3 Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT00054756 2018-08-08
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01582061 2018-06-19
SEASCAPE
Novartis
Phase 3 Completed
NCT02084134 2018-04-11
Steroid
Washington University School of Medicine
Phase NA Completed
NCT01137682 2018-04-05
PAOLA
Novartis
Phase 3 Completed
NCT01371643 2016-08-29
Surgical Debulking of Pituitary Adenomas
NYU Langone Health
Phase 4 Completed
NCT01322945 2013-12-10
BNI
St. Joseph's Hospital and Medical Center, Phoenix
Completed